文献速递慢性肾脏病

达格列净在非糖尿病4期CKD的随机试验

Randomized Trial of Dapagliflozin in Patients With Nondiabetic Stage 4 CKD.
PubMed 文献 · Kidney Int Rep · 2025-07-24

这项前瞻性随机交叉安慰剂对照双盲研究在31例非糖尿病4期CKD且蛋白尿>0.5 g/24h的白人患者中比较达格列净10 mg/d与安慰剂6周的效果。达格列净显著降低GFR(1.88±5.00 ml/min/1.73m²,P=0.022)和蛋白尿(0.50 g/24h,P=0.026),且1周即显著,停药后完全逆转,无严重不良事件。

要点

  • 达格列净6周显著降低非糖尿病4期CKD患者GFR和蛋白尿。
  • GFR下降与肾血浆流量增加及出球小动脉阻力降低相关。
  • 停药后所有变化完全逆转,无严重不良事件。

核心结论

  • 达格列净在非糖尿病终末期前CKD患者中安全改善肾小球高滤过和蛋白尿,并引起尿糖排泄。
  • GFR下降可能源于出球小动脉扩张而非入球小动脉收缩。

研究设计与样本

  • 前瞻性、随机、交叉、安慰剂对照、双盲研究,纳入31例非糖尿病白人4期CKD且蛋白尿>0.5 g/24h的成人。
  • 比较达格列净10 mg/d与安慰剂各治疗6周,主要结局为碘海醇血浆清除率测定的归一化GFR和24小时蛋白尿(3次测量中位数)。
  • 分析采用改良意向性治疗。

主要发现

  • 6周时达格列净较安慰剂显著降低GFR 1.88±5.00 ml/min/1.73m²(P=0.022)和蛋白尿0.50(-0.10至0.80)g/24h(P=0.026)。
  • 达格列净诱导的GFR(P<0.001)和蛋白尿(P=0.003)下降在1周时已显著。
  • 6周时达格列净还降低绝对GFR(P=0.026)、CKD-Epi eGFR(P=0.003)、MDRD eGFR(P=0.002)、24小时白蛋白尿(P=0.001)、总蛋白(P=0.057)和白蛋白(P=0.009)分数清除率及空腹血糖(P<0.001)。
  • 6周时达格列净升高血清白蛋白(P=0.001)、肾素活性(P=0.020)、尿糖(P<0.001)和葡萄糖分数清除率(P<0.001)。
  • 所有变化停药后完全逆转;GFR变化与肾血浆流量变化负相关(P=0.010),与出球小动脉阻力变化正相关(P<0.001),与入球小动脉阻力变化无关。

临床怎么用

  • 在非糖尿病4期CKD伴蛋白尿患者中,达格列净可安全降低蛋白尿,但需监测GFR的初始下降。
  • GFR下降可能与出球小动脉扩张有关,提示血流动力学效应。

局限性

  • 样本量小(31例),仅限非糖尿病白人4期CKD患者。
  • 治疗期短(6周),未评估长期肾脏结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are nephroprotective in patients with chronic kidney disease (CKD) and mild-to-moderate renal insufficiency. METHODS: This prospective, randomized, cross-over, placebo-controlled, double-blind study compared the effects of 6-week dapagliflozin (10 mg/d) with placebo treatment in 31 consenting nondiabetic Caucasian adults with stage 4 CKD and proteinuria > 0.5 g/24 h. Participants were identified at the Nephrology Unit of Papa Giovanni XXIII Hospital and treated at Mario Negri Institute (Bergamo, Italy) between December 2021 and December 2023. Normalized glomerular filtration rate (GFR) (using iohexol plasma clearance) and 24-hour proteinuria (median of 3 urinary measurements) were co-primary outcomes. Analyses were by modified intention-to-treat. RESULTS: At 6 weeks, dapagliflozin significantly decreased GFR by 1.88 ± 5.00 ml/min per 1.73 m2 (P = 0.022) and proteinuria by 0.50 (-0.10 to 0.80) g/24 h (P = 0.026) versus placebo. The dapagliflozin-induced GFR (P < 0.001) and proteinuria (P = 0.003) reduction was already significant at 1 week. At 6 weeks, dapagliflozin reduced absolute GFR (P = 0.026), the CKD-Epidemiology Collaboration (CKD-Epi) equation-based estimated GFR (eGFR) (P = 0.003), the Modification of Diet in Renal Disease (MDRD) equation-based eGFR (P = 0.002), 24-hour albuminuria (P = 0.001), total protein (P = 0.057) and albumin (P = 0.009) fractional clearances, and fasting blood glucose (P < 0.001); and increased serum albumin (P = 0.001), renin activity (P = 0.020), glucosuria (P < 0.001), and glucose fractional clearance (P < 0.001) versus placebo. All changes reversed completely after treatment withdrawal. GFR changes correlated inversely with changes in renal plasma flow (RPF) (P = 0.010) and positively with changes in postglomerular resistance (P < 0.001) but did not correlate with changes in preglomerular resistance. There were no serious adverse events. CONCLUSION: Dapagliflozin safely ameliorates (compensatory) glomerular hyperfiltration and proteinuria and is glycosuric in nondiabetic patients with preterminal CKD. GFR reduction is likely because of postglomerular vasodilation rather than preglomerular vasoconstriction.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Trillini M, Villa A, Perna A, et al. Randomized Trial of Dapagliflozin in Patients With Nondiabetic Stage 4 CKD. Kidney Int Rep. 2025. PMID: 41141510. doi:10.1016/j.ekir.2025.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。